C. Garrison Fathman

Publications

• Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3. Yip L, Creusot RJ, Pager CT, Sarnow P, Fathman CG. J Mol Cell Biol. 2013; 5 (2): 99-110
• Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis. Lin JT, Stein EA, Wong MT, Kalpathy KJ, Su LL, Utz PJ, Robinson WH, Fathman CG. Clin Immunol. 2012; 142 (2): 127-38
• Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC. Nature. 2012; 484 (7395): 529-33
• New tools for classification and monitoring of autoimmune diseases. Maecker HT, Lindstrom TM, Robinson WH, Utz PJ, Hale M, Boyd SD, Shen-Orr SS, Fathman CG. Nat Rev Rheumatol. 2012; 8 (6): 317-28
• Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins. Rothbard JB, Kurnellas MP, Brownell S, Adams CM, Su L, Axtell RC, Chen R, Fathman CG, Robinson WH, Steinman L. J Biol Chem. 2012; 287 (13): 9708-21
• GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness. Whiting CC, Su LL, Lin JT, Fathman CG. FEBS J. 2011; 278 (1): 47-58
• A model for harmonizing flow cytometry in clinical trials. Maecker HT, McCoy JP, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R, Banchereau J, Boshoff C, Braun J, Korin Y, Reed E, Cho J, Hafler D, Davis M, Fathman CG, Robinson W, Denny T, Weinhold K, Desai B, Diamond B, Gregersen P, Di Meglio P, DiMeglio P, Nestle FO, Nestle F, Peakman M, Villanova F, Villnova F, Ferbas J, Field E, Kantor A, Kawabata T, Komocsar W, Lotze M, Nepom J, Ochs H, O'Lone R, Phippard D, Plevy S, Rich S, Roederer M, Rotrosen D, Yeh JH. Nat Immunol. 2010; 11 (11): 975-8
• A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. Mol Ther. 2010; 18 (12): 2112-20
• New technologies for autoimmune disease monitoring. Maecker HT, Nolan GP, Fathman CG. Curr Opin Endocrinol Diabetes Obes. 2010; 17 (4): 322-8
• Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes. Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, Albert PR, Collier AR, Turley SJ, Fathman CG, Creusot RJ. Nat Immunol. 2009; 10 (9): 1026-33
• Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Creusot RJ, Yaghoubi SS, Chang P, Chia J, Contag CH, Gambhir SS, Fathman CG. Blood. 2009; 113 (26): 6638-47
• Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression. Lin JT, Lineberry NB, Kattah MG, Su LL, Utz PJ, Fathman CG, Wu L. J Immunol. 2009; 182 (10): 5919-28
• The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells. Su LL, Iwai H, Lin JT, Fathman CG. J Immunol. 2009; 183 (1): 438-44
• Cutting edge: The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy. Lineberry NB, Su LL, Lin JT, Coffey GP, Seroogy CM, Fathman CG. J Immunol. 2008; 181 (3): 1622-6
• The single subunit transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane. Lineberry N, Su L, Soares L, Fathman CG. J Biol Chem. 2008; 283 (42): 28497-505
• Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice. Kodama K, Butte AJ, Creusot RJ, Su L, Sheng D, Hartnett M, Iwai H, Soares LR, Fathman CG. Clin Immunol. 2008; 129 (2): 195-201
• Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, Thielemans K, Gambhir SS, Fathman CG. Clin Immunol. 2008; 127 (2): 176-87
• Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws. Yaghoubi SS, Creusot RJ, Ray P, Fathman CG, Gambhir SS. J Biomed Opt. 2007 Nov-Dec; 12 (6): 064025
• Molecular mechanisms of CD4+ T-cell anergy. Fathman CG, Lineberry NB. Nat Rev Immunol. 2007; 7 (8): 599-609
• Naive and memory T cells induce different types of graft-versus-host disease. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR, Fathman CG, Strober S. J Immunol. 2007; 179 (10): 6547-54
• A novel E3 ubiquitin ligase substrate screen identifies Rho guanine dissociation inhibitor as a substrate of gene related to anergy in lymphocytes. Su L, Lineberry N, Huh Y, Soares L, Fathman CG. J Immunol. 2006; 177 (11): 7559-66
• CYLD: deubiquitination-induced TCR signaling. Lineberry N, Fathman CG. Nat Immunol. 2006; 7 (4): 369-70
• Cd4+Cd25+ regulatory T cells and their therapeutic potential. Randolph DA, Fathman CG. Annu Rev Med. 2006: 57 381-402
• Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Tarner IH, Neumann E, Gay S, Fathman CG, Müller-Ladner U. Autoimmun Rev. 2006; 5 (2): 148-52
• T cell anergy: where it's LAT. Lineberry N, Fathman CG. Immunity. 2006; 24 (5): 501-3
• An array of possibilities for the study of autoimmunity. Fathman CG, Soares L, Chan SM, Utz PJ. Nature. 2005; 435 (7042): 605-11
• Fostering interdisciplinary immunology Huston, David P., Utz Paul J., Fathman C. Garrison. Clinical Immunology. 2005: 115 1-2
• L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Dutt S, Ermann J, Tseng D, Liu YP, George TI, Fathman CG, Strober S. Blood. 2005; 106 (12): 4009-15
• Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Cao YA, Bachmann MH, Beilhack A, Yang Y, Tanaka M, Swijnenburg RJ, Reeves R, Taylor-Edwards C, Schulz S, Doyle TC, Fathman CG, Robbins RC, Herzenberg LA, Negrin RS, Contag CH. Transplantation. 2005; 80 (1): 134-9
• Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Ermann J, Hoffmann P, Edinger M, Dutt S, Blankenberg FG, Higgins JP, Negrin RS, Fathman CG, Strober S. Blood. 2005; 105 (5): 2220-6
• Protein microarrays for multiplex analysis of signal transduction pathways Chan, Steven M., Ermann, Joerg, Su, Leon, Fathman, C. Garrison and Utz, Paul J.. Nature Medicine. 2005: 10 1390-1396
• Targeted gene therapy of autoimmune diseases: advances and prospects. Creusot RJ, Fathman CG, Müller-Ladner U, Tarner IH. Expert Rev Clin Immunol. 2005; 1 (3): 385-404
• Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity. Creusot RJ, Fathman CG. J Clin Invest. 2004; 114 (7): 892-4
• Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. Su L, Creusot RJ, Gallo EM, Chan SM, Utz PJ, Fathman CG, Ermann J. J Immunol. 2004; 173 (8): 4994-5001
• Protein microarrays for multiplex analysis of signal transduction pathways. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ. Nat Med. 2004; 10 (12): 1390-6
• The gene related to anergy in lymphocytes, an E3 ubiquitin ligase, is necessary for anergy induction in CD4 T cells. Seroogy CM, Soares L, Ranheim EA, Su L, Holness C, Bloom D, Fathman CG. J Immunol. 2004; 173 (1): 79-85
• Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Soares L, Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD, Engleman E, Fathman CG. Nat Immunol. 2004; 5 (1): 45-54
• CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS. Nat Med. 2003; 9 (9): 1144-50
• Costimulatory signals controlling regulatory T cells. Ermann J, Fathman CG. Proc Natl Acad Sci U S A. 2003; 100 (26): 15292-3
• GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Anandasabapathy N, Ford GS, Bloom D, Holness C, Paragas V, Seroogy C, Skrenta H, Hollenhorst M, Fathman CG, Soares L. Immunity. 2003; 18 (4): 535-47
• Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis. Smith R, Tarner IH, Hollenhorst M, Lin C, Levicnik AU, Fathman CG, Nolan GP. Gene Ther. 2003; 10 (15): 1248-57
• Scratching the (T cell) surface. Ermann J, Chung CD, Fathman CG. Genome Biol. 2003; 5 (1): 202
• Treatment of autoimmune disease by adoptive cellular gene therapy. Tarner IH, Slavin AJ, McBride J, Levicnik A, Smith R, Nolan GP, Contag CH, Fathman CG. Ann N Y Acad Sci. 2003: 998 512-9
• A complicated relationship: fulfilling the interactive needs of the T lymphocyte and the dendritic cell. McBride JM, Fathman CG. Pharmacogenomics J. 2002; 2 (6): 367-76
• Adoptive cellular gene therapy of autoimmune disease. Slavin AJ, Tarner IH, Nakajima A, Urbanek-Ruiz I, McBride J, Contag CH, Fathman CG. Autoimmun Rev. 2002; 1 (4): 213-9
• CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. Oh JW, Seroogy CM, Meyer EH, Akbari O, Berry G, Fathman CG, Dekruyff RH, Umetsu DT. J Allergy Clin Immunol. 2002; 110 (3): 460-8
• Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. J Exp Med. 2002; 196 (3): 389-99
• Immunomodulatory vaccination in autoimmune disease. Urbanek-Ruiz I, Ruiz PJ, Steinman L, Fathman CG. Endocrinol Metab Clin North Am. 2002; 31 (2): 441-56, viii-ix
• Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Tarner IH, Nakajima A, Seroogy CM, Ermann J, Levicnik A, Contag CH, Fathman CG. Clin Immunol. 2002; 105 (3): 304-14
• Short polymers of arginine rapidly translocate into vascular cells: effects on nitric oxide synthesis. Uemura S, Rothbard JB, Matsushita H, Tsao PS, Fathman CG, Cooke JP. Circ J. 2002; 66 (12): 1155-60
• The potential for gene therapy in the treatment of autoimmune disease. Tarner IH, Fathman CG. Clin Immunol. 2002; 104 (3): 204-16
• The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. J Immunol. 2002; 169 (5): 2461-5
• Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. Costa GL, Sandora MR, Nakajima A, Nguyen EV, Taylor-Edwards C, Slavin AJ, Contag CH, Fathman CG, Benson JM. J Immunol. 2001; 167 (4): 2379-87
• Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis. Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL, Taylor-Edwards C, Bachmann MH, Contag CH, Fathman CG. J Clin Invest. 2001; 107 (10): 1293-301
• Autoimmune diseases: genes, bugs and failed regulation. Ermann J, Fathman CG. Nat Immunol. 2001; 2 (9): 759-61
• Bioluminescence imaging of lymphocyte trafficking in vivo. Hardy J, Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH. Exp Hematol. 2001; 29 (12): 1353-60
• CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG, Lejon K. J Immunol. 2001; 167 (8): 4271-5
• Gene therapy in autoimmune disease. Tarner IH, Fathman CG. Curr Opin Immunol. 2001; 13 (6): 676-82
• Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG. Clin Immunol. 2001; 100 (2): 164-71
• Application of gene therapy in autoimmune disease. Fathman CG, Seroogy CM. Curr Dir Autoimmun. 2000: 2 189-202
• Gene therapy for autoimmune disease. Fathman CG, Costa GL, Seroogy CM. Clin Immunol. 2000; 95 (1 Pt 2): S39-43
• Identification and characterization of the antigen-specific subpopulation of alloreactive CD4+ T cells in vitro and in vivo. Krieger NR, Fathman CG, Shaw MK, Ridgway WM. Transplantation. 2000; 69 (4): 605-9
• Polyarginine enters cells more efficiently than other polycationic homopolymers. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. J Pept Res. 2000; 56 (5): 318-25
• Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia. Uemura S, Fathman CG, Rothbard JB, Cooke JP. Circulation. 2000; 102 (21): 2629-35
• T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo. Fassò M, Anandasabapathy N, Crawford F, Kappler J, Fathman CG, Ridgway WM. J Exp Med. 2000; 192 (12): 1719-30
• Targeting rare populations of murine antigen-specific T lymphocytes by retroviral transduction for potential application in gene therapy for autoimmune disease. Costa GL, Benson JM, Seroogy CM, Achacoso P, Fathman CG, Nolan GP. J Immunol. 2000; 164 (7): 3581-90
• The application of gene therapy in autoimmune diseases. Seroogy CM, Fathman CG. Gene Ther. 2000; 7 (1): 9-13
• A new look at MHC and autoimmune disease. Ridgway WM, Fassò M, Fathman CG. Science. 1999; 284 (5415): 749, 751
• Isolation of self antigen-reactive cells from inflamed islets of nonobese diabetic mice using CD4high expression as a marker. Lejon K, Fathman CG. J Immunol. 1999; 163 (10): 5708-14
• Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis. Dal Canto RA, Shaw MK, Nolan GP, Steinman L, Fathman CG. Clin Immunol. 1999; 90 (1): 10-4
• Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: modulation of T cell costimulation. Ruiz PJ, Garren H, Ruiz IU, Hirschberg DL, Nguyen LV, Karpuj MV, Cooper MT, Mitchell DJ, Fathman CG, Steinman L. J Immunol. 1999; 162 (6): 3336-41
• A gene therapy approach to treatment of autoimmune disease. Seroogy CM, Fathman CG. Immunol Res. 1998; 18 (1): 15-26
• Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response. Ridgway WM, Ito H, Fassò M, Yu C, Fathman CG. J Exp Med. 1998; 188 (12): 2267-75
• Following antigen challenge, T cells up-regulate cell surface expression of CD4 in vitro and in vivo. Ridgway W, Fassò M, Fathman CG. J Immunol. 1998; 161 (2): 714-20
• Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates. Krieger NR, Yuh D, McIntyre WB, Flavin TF, Yin D, Robbins R, Fathman CG. J Surg Res. 1998; 76 (2): 174-8
• Regulation of programmed cell death following T cell activation in vivo. Yang Y, Kim D, Fathman CG. Int Immunol. 1998; 10 (2): 175-83
• T cell receptor (TCR) engagement leads to activation-induced splicing of tumor necrosis factor (TNF) nuclear pre-mRNA. Yang Y, Chang JF, Parnes JR, Fathman CG. J Exp Med. 1998; 188 (2): 247-54
• The association of MHC with autoimmune diseases: understanding the pathogenesis of autoimmune diabetes. Ridgway WM, Fathman CG. Clin Immunol Immunopathol. 1998; 86 (1): 3-10
• CD45RBhigh CD4+ T cells from IFN-gamma knockout mice do not induce wasting disease. Ito H, Fathman CG. J Autoimmun. 1997; 10 (5): 455-9
• Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. J Immunol. 1997; 159 (4): 1666-8
• Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. Shaw MK, Lorens JB, Dhawan A, DalCanto R, Tse HY, Tran AB, Bonpane C, Eswaran SL, Brocke S, Sarvetnick N, Steinman L, Nolan GP, Fathman CG. J Exp Med. 1997; 185 (9): 1711-4
• Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice. Krieger NR, Ito H, Fathman CG. J Autoimmun. 1997; 10 (3): 309-15
• The use of CD4 and CD8 knockout mice to study the role of T-cell subsets in allotransplant rejection. Krieger NR, Fathman CG. J Heart Lung Transplant. 1997; 16 (3): 263-7
• Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Shimada A, Charlton B, Taylor-Edwards C, Fathman CG. Diabetes. 1996; 45 (8): 1063-7
• Breaking self-tolerance in nonobese diabetic mice. Ridgway WM, Fassò M, Lanctot A, Garvey C, Fathman CG. J Exp Med. 1996; 183 (4): 1657-62
• CD4+ but not CD8+ cells are essential for allorejection. Krieger NR, Yin DP, Fathman CG. J Exp Med. 1996; 184 (5): 2013-8
• Immune regulation in type 1 diabetes. Shimada A, Charlton B, Rohane P, Taylor-Edwards C, Fathman CG. J Autoimmun. 1996; 9 (2): 263-9
• Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Yin DP, Sankary HN, Williams J, Krieger N, Fathman CG. Transplantation. 1996; 62 (11): 1537-9
• Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG. J Immunol. 1996; 156 (1): 5-7
• Monoclonal T cells identified in early NOD islet infiltrates. Yang Y, Charlton B, Shimada A, Dal Canto R, Fathman CG. Immunity. 1996; 4 (2): 189-94
• Pathogenic and protective roles of CD45RB(low) CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Shimada A, Rohane P, Fathman CG, Charlton B. Diabetes. 1996; 45 (1): 71-8
• Quantitative analysis of T cell activation: role of TCR/ligand density and TCR affinity. Kim DT, Rothbard JB, Bloom DD, Fathman CG. J Immunol. 1996; 156 (8): 2737-42
• Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, Martin R, Utz U, Karin N, Mitchell D, Veromaa T, Waisman A, Gaur A, Conlon P, Ling N, Fairchild PJ, Wraith DC, O'Garra A, Fathman CG, Steinman L. Nature. 1996; 379 (6563): 343-6
• CD4-positive suppressor cells block allotransplant rejection. Yin D, Fathman CG. J Immunol. 1995; 154 (12): 6339-45
• Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig. Yin D, Fathman CG. J Immunol. 1995; 155 (4): 1655-9
• Islet-infiltrating lymphocytes from prediabetic NOD mice rapidly transfer diabetes to NOD-scid/scid mice. Rohane PW, Shimada A, Kim DT, Edwards CT, Charlton B, Shultz LD, Fathman CG. Diabetes. 1995; 44 (5): 550-4
• Ternary complex therapy for autoimmune disease. Fathman CG, Hosp Pract (1995). 1995; 30 (8): 57-8, 60-2, 64-5
• Tissue-specific effects of anti-CD4 therapy in induction of allograft unresponsiveness in high and low responder rats. Yin D, Fathman CG. Transpl Immunol. 1995; 3 (3): 258-64
• CD4-positive/heat-stable antigen-positive thymocytes cause graft-versus-host disease across non-major histocompatibility complex incompatibilities. Charlton B, Meltzer J, Fathman CG. Eur J Immunol. 1994; 24 (7): 1706-9
• Immunotherapeutic strategies directed at the trimolecular complex. Gaur A, Fathman CG. Adv Immunol. 1994: 56 219-65
• Mechanisms of transplantation tolerance. Charlton B, Auchincloss H, Fathman CG. Annu Rev Immunol. 1994: 12 707-34
• Prevention of diabetes and insulitis by neonatal intrathymic islet administration in NOD mice. Charlton B, Taylor-Edwards C, Tisch R, Fathman CG. J Autoimmun. 1994; 7 (5): 549-60
• Regulation of autoimmune response. Ridgway WM, Weiner HL, Fathman CG. Curr Opin Immunol. 1994; 6 (6): 946-55
• Anti-CD4 antibodies in diabetes. Shizuru JA, Fathman CG. Immunol Ser. 1993: 59 237-52
• Evidence that anti-CD8 abrogates anti-CD4-mediated clonal anergy but allows allograft survival in mice. Song HK, Alters SE, Fathman CG. Transplantation. 1993; 55 (1): 133-9
• Evidence that clonal anergy is induced in thymic migrant cells after anti-CD4-mediated transplantation tolerance. Alters SE, Song HK, Fathman CG. Transplantation. 1993; 56 (3): 633-8
• Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Brocke S, Gaur A, Piercy C, Gautam A, Gijbels K, Fathman CG, Steinman L. Nature. 1993; 365 (6447): 642-4
• Peptides as therapy of autoimmune disease. Fathman CG, Diabetes Metab Rev. 1993; 9 (4): 239-44
• Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness. Gaur A, Ruberti G, Haspel R, Mayer JP, Fathman CG. Science. 1993; 259 (5091): 91-4
• SEB induced anergy: modulation of immune response to T cell determinants of myoglobin and myelin basic protein. Gaur A, Fathman CG, Steinman L, Brocke S. J Immunol. 1993; 150 (7): 3062-9
• Selection for amino acid sequence and J beta element usage in the beta chain of DBA/2V beta b- and DBA/2V beta a-derived myoglobin-specific T cell clones. Ruberti G, Paragas V, Kim D, Fathman CG. J Immunol. 1993; 151 (11): 6185-94
• The use of granzyme A as a marker of heart transplant rejection in cyclosporine or anti-CD4 monoclonal antibody-treated rats. Chen RH, Ivens KW, Alpert S, Billingham ME, Fathman CG, Flavin TF, Shizuru JA, Starnes VA, Weissman IL, Griffiths GM. Transplantation. 1993; 55 (1): 146-53
• Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Science. 1992; 258 (5087): 1491-4
• Anti-CD4 monoclonal antibodies in therapy: creation of nonclassical tolerance in the adult. Shizuru JA, Alters SE, Fathman CG. Immunol Rev. 1992: 129 105-30
• Immunotherapy of rheumatic diseases based on understanding genetic predisposition to the development of these diseases. Fathman CG, Rheum Dis Clin North Am. 1992; 18 (4): 915-26
• Limited T cell receptor beta-chain usage in the sperm whale myoglobin 110-121/E alpha dA beta d response by H-2d congenic mouse strains. Sellins KS, Danska JS, Paragas V, Fathman CG. J Immunol. 1992; 149 (7): 2323-7
• Presentation of antigen by mixed isotype class II molecules in normal H-2d mice. Ruberti G, Sellins KS, Hill CM, Germain RN, Fathman CG, Livingstone A. J Exp Med. 1992; 175 (1): 157-62
• What a rheumatologist needs to know about T cell receptor structure and function. Fathman CG, J Rheumatol Suppl. 1992: 32 12-5; discussion 15-7
• Analysis of the ternary complex of antigen, MHC and T-cell receptor: the influence of the T-cell receptor V beta repertoire on the V beta gene element usage. Ruberti G, Livingstone A, Danska JS, Gaur A, Fathman CG. Res Immunol. 1991 Jun-Aug; 142 (5-6): 491-3
• Anti-CD4 mediates clonal anergy during transplantation tolerance induction. Alters SE, Shizuru JA, Ackerman J, Grossman D, Seydel KB, Fathman CG. J Exp Med. 1991; 173 (2): 491-4
• Anti-CD8 abrogates effect of anti-CD4-mediated islet allograft survival in rat model. Seydel K, Shizuru J, Grossman D, Wu A, Alters S, Fathman CG. Diabetes. 1991; 40 (11): 1430-4
• Genetic analysis of diabetes in the nonobese diabetic mouse. I. MHC and T cell receptor beta gene expression. Livingstone A, Edwards CT, Shizuru JA, Fathman CG. J Immunol. 1991; 146 (2): 529-34
• Genetic dissection of T cell receptor V beta gene requirements for spontaneous murine diabetes. Shizuru JA, Taylor-Edwards C, Livingstone A, Fathman CG. J Exp Med. 1991; 174 (3): 633-8
• Molecular analysis of the role of the HLA class II genes DRB1, DQA1, DQB1, and DPB1 in susceptibility to Lyme arthritis. Ruberti G, Begovich AB, Steere AC, Klitz W, Erlich HA, Fathman CG. Hum Immunol. 1991; 31 (1): 20-7
• The T cell receptor repertoire influences V beta element usage in response to myoglobin. Ruberti G, Gaur A, Fathman CG, Livingstone AM. J Exp Med. 1991; 174 (1): 83-92
• Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy. Shizuru JA, Seydel KB, Flavin TF, Wu AP, Kong CC, Hoyt EG, Fujimoto N, Billingham ME, Starnes VA, Fathman CG. Transplantation. 1990; 50 (3): 366-73
• Shared molecular markers of genetic predisposition to seropositive rheumatoid arthritis. Morel PA, Horn GT, Budd RC, Erlich HA, Fathman CG. Hum Immunol. 1990; 27 (2): 90-9
• T cell receptor-mediated negative selection of autoreactive T lymphocyte precursors occurs after commitment to the CD4 or CD8 lineages. Guidos CJ, Danska JS, Fathman CG, Weissman IL. J Exp Med. 1990; 172 (3): 835-45
• The presumptive CDR3 regions of both T cell receptor alpha and beta chains determine T cell specificity for myoglobin peptides. Danska JS, Livingstone AM, Paragas V, Ishihara T, Fathman CG. J Exp Med. 1990; 172 (1): 27-33
• A subset of memory CD4+ helper T lymphocytes identified by expression of Pgp-1. Butterfield K, Fathman CG, Budd RC. J Exp Med. 1989; 169 (4): 1461-6
• Cardiac allograft prolongation in mice treated with combined posttransplantation total-lymphoid irradiation and anti-L3T4 antibody therapy. Trager DK, Banks BA, Rosenbaum GE, Holm BI, Shizuru JA, Strober S, Fathman CG. Transplantation. 1989; 47 (4): 587-91
• Enhanced cell-mediated protection against fatal Escherichia coli septicemia induced by treatment with recombinant IL-2. Goronzy J, Weyand C, Quan J, Fathman CG, O'Hanley P. J Immunol. 1989; 142 (4): 1134-8
• A new look at the shared epitope hypothesis. Morel PA, Erlich HA, Fathman CG. Am J Med. 1988; 85 (6A): 20-2
• Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG. Science. 1988; 240 (4852): 659-62
• Use of anti-L3T4 and anti-Ia treatments for prolongation of xenogeneic islet transplants. Kaufman DS, Kong CS, Shizuru JA, Gregory AK, Fathman CG. Transplantation. 1988; 46 (2): 210-5